NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on brain and central nervous system cancer treatments, was featured on Yahoo Finance's Trader Talk podcast. The episode highlights the company's recent achievements, including its successful IPO, a $50 million partnership in the Middle East, and inclusion in the Russell Microcap Index.
The podcast discussion with Executive Chairman Amir Heshmatpour covers NeOnc's innovative intranasal drug delivery approach for brain cancer, its strategic partnership with USC's medical school, and the expansion of global clinical trials. The conversation also explores the potential impact of AI and quantum computing in biotechnology.
NeOnc Technologies (NASDAQ: NTHI), una società biotecnologica in fase clinica focalizzata sui trattamenti per il cancro al cervello e al sistema nervoso centrale, è stata protagonista del podcast Trader Talk di Yahoo Finance. L'episodio mette in evidenza i recenti successi dell'azienda, tra cui la sua IPO di successo, una partnership da 50 milioni di dollari in Medio Oriente e l'inclusione nell'indice Russell Microcap.
La discussione nel podcast con il Presidente Esecutivo Amir Heshmatpour affronta l'innovativo metodo di somministrazione intranasale dei farmaci per il cancro cerebrale di NeOnc, la partnership strategica con la facoltà di medicina della USC e l'espansione degli studi clinici a livello globale. La conversazione esplora inoltre l'impatto potenziale di IA e calcolo quantistico nel campo della biotecnologia.
NeOnc Technologies (NASDAQ: NTHI), una empresa biotecnológica en etapa clínica enfocada en tratamientos para el cáncer cerebral y del sistema nervioso central, fue destacada en el podcast Trader Talk de Yahoo Finance. El episodio resalta los logros recientes de la compañía, incluyendo su exitosa oferta pública inicial, una asociación de 50 millones de dólares en Medio Oriente y su inclusión en el índice Russell Microcap.
La conversación en el podcast con el Presidente Ejecutivo Amir Heshmatpour aborda el innovador enfoque de administración intranasal de medicamentos para el cáncer cerebral de NeOnc, su alianza estratégica con la facultad de medicina de USC y la expansión de ensayos clínicos globales. Además, se explora el impacto potencial de la IA y la computación cuántica en la biotecnología.
NeOnc Technologies (NASDAQ: NTHI)는 뇌 및 중추신경계 암 치료에 중점을 둔 임상 단계 바이오테크 기업으로, Yahoo Finance의 Trader Talk 팟캐스트에 소개되었습니다. 이번 에피소드에서는 성공적인 기업공개(IPO), 중동 지역 5천만 달러 규모의 파트너십, 그리고 러셀 마이크로캡 지수 편입 등 회사의 최근 성과를 강조합니다.
Executive Chairman Amir Heshmatpour와의 팟캐스트 대화에서는 NeOnc의 뇌암 치료를 위한 혁신적인 비강 투여 방식, USC 의과대학과의 전략적 파트너십, 글로벌 임상 시험 확장에 대해 다룹니다. 또한 바이오테크 분야에서의 인공지능과 양자컴퓨팅의 잠재적 영향도 탐구합니다.
NeOnc Technologies (NASDAQ : NTHI), une société biotechnologique en phase clinique spécialisée dans les traitements des cancers du cerveau et du système nerveux central, a été mise en avant dans le podcast Trader Talk de Yahoo Finance. L'épisode met en lumière les récentes réussites de l'entreprise, notamment son introduction en bourse réussie, un partenariat de 50 millions de dollars au Moyen-Orient et son inclusion dans l'indice Russell Microcap.
La discussion du podcast avec le président exécutif Amir Heshmatpour aborde l'approche innovante de NeOnc pour l'administration intranasale de médicaments contre le cancer du cerveau, son partenariat stratégique avec la faculté de médecine de l'USC, ainsi que l'expansion des essais cliniques mondiaux. La conversation explore également l'impact potentiel de l'IA et de l'informatique quantique dans le domaine de la biotechnologie.
NeOnc Technologies (NASDAQ: NTHI), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Behandlungen von Gehirn- und zentralnervösen Systemkrebsen spezialisiert hat, wurde im Trader Talk Podcast von Yahoo Finance vorgestellt. Die Folge hebt die jüngsten Erfolge des Unternehmens hervor, darunter den erfolgreichen Börsengang, eine 50-Millionen-Dollar-Partnerschaft im Nahen Osten und die Aufnahme in den Russell Microcap Index.
Im Podcast-Gespräch mit Executive Chairman Amir Heshmatpour wird NeOncs innovativer intranasaler Wirkstoffverabreichungsansatz für Gehirntumore, die strategische Partnerschaft mit der medizinischen Fakultät der USC sowie die Ausweitung globaler klinischer Studien besprochen. Außerdem wird das potenzielle Einflussfeld von Künstlicher Intelligenz und Quantencomputing in der Biotechnologie erörtert.
- Secured significant $50 million partnership in Middle East
- Successfully completed IPO despite challenging market conditions
- Added to Russell Microcap Index, increasing visibility to investors
- Strategic partnership with USC medical school enhancing research capabilities
- Expanding global clinical trials footprint
- Early-stage company still in Phase 2 clinical trials
- Operating in highly competitive biotech sector
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance’s Trader Talk with Kenny Polcari in a podcast episode titled “AI and Biotech Take on Brain Cancer.”
As Trader Talk describes it: “When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (Nasdaq: NTHI), about how the company defied a tough market to go public, secure a
You can tune in to the episode on Apple Podcasts, Spotify, YouTube, or wherever you listen to your podcasts.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
What major partnership did NeOnc Technologies (NTHI) secure in 2025?
What is NeOnc Technologies' (NTHI) main focus in cancer treatment?
When did NeOnc Technologies (NTHI) join the Russell Microcap Index?
What is NeOnc Technologies' (NTHI) partnership with USC?
How is NeOnc Technologies (NTHI) incorporating AI in their research?
